PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / March 2, 2026 / Prolocor, Inc., a healthcare company developing the innovative diagnostic Prolocor pFCG test to identify patients at risk of thrombotic events, today announced that its recent publication, entitled "Prognostic Implications Over Time of Platelet Fc?RIIa Expression in Patients with Myocardial Infarction," has been selected by the Journal of Invasive Cardiology (JIC) as one of the Editors' Top 10 Articles of 2025.
The recognized research highlights the powerful prognostic value of the pFCG test in the critical months following a heart attack. The study found that patients with high platelet Fc?RIIa expression faced a significantly higher risk of the composite endpoint of death, MI, or stroke, particularly within the first 30 days.
Expert Insight: Dr. Deepak L. Bhatt Interviews Dr. David Schneider
In conjunction with this recognition, Deepak L. Bhatt, MD, MPH, Editor-in-Chief of the Journal of Invasive Cardiology, hosted an in-depth interview with the study's lead author and Prolocor Co-Founder, David Schneider, MD, FACC, FAHA.
During the discussion, Dr. Schneider elaborated on how the Fc?RIIa receptors on a patient's platelets acts as a biological "accelerant" for thrombosis, and how a greater number of these receptors is associated with a higher risk. identifying this high-risk phenotype can guide clinicians in individualizing dual antiplatelet therapy (DAPT).
Key Study Findings:
Early Risk Stratification: The pFCG test demonstrated its greatest prognostic power early after a myocardial infarction (MI), with a Hazard Ratio (HR) of 3.84 (P=.0009) in the first month.
Sustained Predictive Value: The HR remained high at 2.90 (P=.00005) through the first six months, effectively identifying patients at risk of recurrent events.
Clinical Utility: The test provides a precise tool for clinicians to balance ischemic and bleeding risks, potentially shifting the paradigm toward precision cardiovascular care.
"This recognition from the Journal of Invasive Cardiology validates the clinical importance of science behind our platform," said Peter DiBattiste, MD, CEO of Prolocor. "Our mission is to support physicians in optimizing antiplatelet therapy. By providing a clear biological marker of risk, we are giving cardiologists the data they need to tailor treatments specifically to the individual patient's biology, improving safety and efficacy across the continuum of care."
"We are honored that the editors have recognized the clinical significance of this work," added Dr. Schneider. "By identifying patients at the highest risk during the most vulnerable period following an MI, the pFCG test empowers physicians to make more informed, personalized treatment decisions."
About Prolocor, Inc.
Founded by a team that deeply understands thrombosis and cardiovascular disease, Prolocor is building its strategy around platelet Fc?RIIa and embarking on a journey to commercialize an innovative precision diagnostic test that quantifies Fc?RIIa on the surface of platelets. For more information on Prolocor, please visit the company's website at www.prolocor.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although Prolocor's management believes that the expectations reflected in such forward-looking statements are reasonable, forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Prolocor, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, Prolocor's planned level of revenues and capital expenditures, Prolocor's available cash and its ability to obtain additional funding, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities regarding whether and when to approve any device or application that may be filed for any such product candidates and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Prolocor's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, and risks associated with intellectual property. Other than as required by applicable law, Prolocor does not undertake any obligation to update or revise any forward-looking information or statements.
Contact
ray.russo@prolocor.com
SOURCE: Prolocor Inc
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/biotechnology/prolocorr-research-named-a-%22top-10-article-of-2025%22-by-the-journal-of-invasive-cardio-1141867
